SCHEDULE: BlackRock Discloses 5.3% Passive Stake in Utah Medical Products Inc.
Beneficial Ownership Disclosure
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.3% of Utah Medical Products Inc.'s common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 172,684 shares of Utah Medical Products Inc. common stock.
- This stake represents 5.3% of the total outstanding common stock of Utah Medical Products Inc.
- BlackRock holds sole voting power over 168,277 shares and sole dispositive power over 172,684 shares.
- No shared voting or dispositive power is reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory disclosure of passive beneficial ownership, providing factual information without indicating positive or negative operational performance or strategic shifts for the issuer.
Positives
- The filing provides transparency regarding a significant institutional investor's passive stake in Utah Medical Products Inc.
- BlackRock's certification confirms the passive nature of the investment, indicating no intent to influence or change control of the issuer.
Negatives
- The Schedule 13G filing does not provide any operational or financial performance insights into Utah Medical Products Inc.
- The document is a standard regulatory disclosure and does not contain information that would typically drive significant positive or negative sentiment regarding the issuer's business.
Risks
- The document itself does not introduce new risks for Utah Medical Products Inc., but rather discloses an existing passive ownership stake.
Future Outlook
The document is a beneficial ownership disclosure and does not provide any forward-looking statements or guidance regarding Utah Medical Products Inc.'s future performance or strategic direction.
Management Comments
- "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
A Schedule 13G filing indicates a passive investment by an institutional investor, such as BlackRock, in a publicly traded company. This type of filing is typically made when an entity acquires more than 5% of a company's voting shares with no intent to influence or control the company's management or operations. It provides market transparency regarding significant ownership stakes.
Stakeholder Impact
- Shareholders gain transparency regarding a significant institutional holder's passive stake in the company.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. authorizing individuals to execute SEC filings. |
| 06/30/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 07/17/2025 | Date the Schedule 13G statement was signed by BlackRock, Inc. |
Keywords
BlackRock, Utah Medical Products Inc., Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.